Therefore, moderate E2F2 gene expression and high or low ECSIT and ID4 gene expression was associated with a lower risk of mortality and disease progression in patients with GBM (except for disease progression at moderate E2F2 expression compared with high E2F2 expression and low ECSIT expression) (Table 3). This evidence concerns the gene E2F2 and glioblastoma.